Henry @BluegrassBio

Recovering scientist focused on small-cap oncology investments. Joined July 2014

Tweets

89
Followers

55
Following

293
Likes

499

Henry @BluegrassBio

2 years ago

@united @united Great job completely shutting down customer support for your 1K members. Absolutely ridiculous that I can't reach a human to help sort out this flight mess.

0 0 0 168 0

View Details

Bishal Gyawali, MD, PhD, FASCO @oncology_bg

5 years ago

This is a great example to understand why informative censoring should be considered in evaluating trials with PFS endpoint. Fantastic viewpoint from Tannock, Pond and Booth @JAMAOnc . jamanetwork.com/journals/jamao…

3 44 137 0 33

View Details

Mr.M @KillerStockCall

5 years ago

Potential Bio Catalysts $ARDX Drug: Tenapanor Date: 29 July 2021 PDUFA $ETON Drug: Topiramate Date: 6 Aug 2021 PDUFA $SESN Drug: Vicinium Date: 18 Aug 2021 PDUFA $KDMN Drug: Belumosudil Date: 30 Aug 2021 PDUFA #Fintwit #StockMarket #Trading #StocksToWatch #StockMarketNews

0 1 15 0 0

View Details

BioBill @BioBill2

5 years ago

$sttk taking one out of the $tril playbook with their own CD47 table.

1 3 10 0 2

View Details

LARVOL @Larvol

5 years ago

Going to #ASCO21? How about the other #oncology conferences coming up this year? We've put together a list of the Top 100 Oncology Conferences in 2021, and have a few ideas to help you maximize your attendance. bit.ly/3tWo7l0

1 3 4 0 0

View Details

Mazeraski @Mazeraski

5 years ago

@pharmacreep @MSollender The price/volume info in my TIGIT spreadsheet is updated dynamically when the market is open. Might be an easy way to track how the $AGEN news affects the other TIGIT players. $AGEN $BGNE $BMY $CGEN $CHRS $ITOS $MREO $MRK $PHIO $RCUS $RIGL $SGEN $SURF docs.google.com/spreadsheets/d…

1 3 14 0 4

View Details

Larry Hsin @xlp007

5 years ago

$AFMD $FATE Very interesting article about TCR-NK. Based on my understanding, the trend of cell therapy will be the off-the-shelf, broad and precise tumour target aiming, large scale manufacturing, fewer side-effects, low cost and easy administration. thelancet.com/journals/ebiom…

3 5 21 0 2

View Details

Ginkgo Bioworks @Ginkgo

6 years ago

*Ginkgo

Adam Feuerstein ✡️ @adamfeuerstein

6 years ago

Sorry, not sorry, but Gingko does not deserve the $DNA ticker.

24 7 129 0 2

22 25 361 0 4

View Details

haodongvli @haodongvli

6 years ago

$IOVA Submitted validated potency assays for lifileucel to FDA, FDA should respond soon! Some reviewers are from NCI, familar with Dr. Rosenberg's work

0 3 7 0 0

View Details

Ming Zhao @FabiusMercurius

6 years ago

🧐How to Read 10Ks Like a Hedge Fund🧐 “Fundamentals don’t matter anymore!” I’ve heard this a lot lately on Fintwit.🙄 But, for those who’ve diversify beyond $GME and $DOGE, here’s a primer on what metrics fundamental buy-side PMs look at and why: (real examples outlined) 👇

272 1K 6K 0 6K

View Details

Vinay Prasad MD MPH @VPrasadMDMPH

6 years ago

Wow! 5 of 6 drugs that were approved via Accelerated Approval (AA) and FAILED legally required post market trials are voted to REMAIN on the US market by the ODAC The very premise of Accelerated Approval falls into question If we cannot enforce AA, can we have it? [thread]

8 52 179 0 27

View Details

Henry @BluegrassBio

9 years ago

@RhettLButler Lol I love that movie. Ice Cube AKA The Don Mega and that smoking hot chick from Species? Can’t beat the cast.

0 0 0 0 0

View Details

Adam Feuerstein ✡️ @adamfeuerstein

9 years ago

This is a very good story, validates concerns of many investors about pace of CAR-T launch and complexities of reimbursement. $GILD $NVS $JUNO x.com/ArmstrongDrew/…